<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84061">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019849</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-O-H-1213</org_study_id>
    <nct_id>NCT02019849</nct_id>
  </id_info>
  <brief_title>Post Market Clinical Follow-Up of Plasmafit® Cup</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap AG</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Twelve months follow-up of implant survival and clinical and radiological follow-up of
      Plasmafit® Cup.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Implant Survival Rates</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Implant survival is analysed at follow-up examinations at 3 months, 12 months, 5 years and 10 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osteolysis</measure>
    <time_frame>3 months, 12 months, 5 years, 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiological Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ossifications</measure>
    <time_frame>3 months, 12 months, 5 years, 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiological Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Position</measure>
    <time_frame>3 months, 12 months, 5 years, 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiological Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migration of Plasmafit®</measure>
    <time_frame>3 months, 12 months, 5 years, 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Radiological Outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome</measure>
    <time_frame>3 months, 12 months, 5 years, 10 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Harris Hip Score</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Plasmafit® Total Hip Arthroplasty</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plasmafit® Total Hip Arthroplasty</intervention_name>
    <description>N/A</description>
    <arm_group_label>Plasmafit® Total Hip Arthroplasty</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Specialist  Clinical Centre
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Minimum age 18 years

          -  Indication for cementless total hip arthroplasty

          -  Patient consent for study participation

          -  Physical and mental willingness to participate at clinical and radiological follow-up

        Exclusion Criteria:

          -  Patient not available for follow-up

          -  Increased anesthetics risks according to the &quot;American Society of Anesthesiology&quot;:
             ASA IV

          -  Tumor

          -  Alcohol or drug abuse

          -  Permanent cortisone therapy

          -  Clinically relevant infection

          -  Pregnancy or planned pregnancy

          -  Prior interventions like osteotomy, fracture treatment or prior THA at the concerned
             hip

          -  Acute fracture at the concerned hip

          -  Patients needing a cemented hip arthroplasty
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vulpius-Klinik Bad Rappenau</name>
      <address>
        <city>Bad Rappenau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 18, 2013</lastchanged_date>
  <firstreceived_date>December 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>THA, Plasmafit®</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
